IN2014CN00315A - - Google Patents

Info

Publication number
IN2014CN00315A
IN2014CN00315A IN315CHN2014A IN2014CN00315A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A IN 315CHN2014 A IN315CHN2014 A IN 315CHN2014A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A
Authority
IN
India
Prior art keywords
directed
methods
subject matter
disclosed subject
presently disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Lacouture
De Rocha Marcelo Garcia
Daniel B Carr
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of IN2014CN00315A publication Critical patent/IN2014CN00315A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN315CHN2014 2011-07-20 2012-07-19 IN2014CN00315A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509886P 2011-07-20 2011-07-20
PCT/US2012/047453 WO2013013076A1 (en) 2011-07-20 2012-07-19 Methods of treating pain

Publications (1)

Publication Number Publication Date
IN2014CN00315A true IN2014CN00315A (enExample) 2015-04-03

Family

ID=47558482

Family Applications (1)

Application Number Title Priority Date Filing Date
IN315CHN2014 IN2014CN00315A (enExample) 2011-07-20 2012-07-19

Country Status (16)

Country Link
US (1) US20140221490A1 (enExample)
EP (2) EP3257505A1 (enExample)
JP (2) JP6320917B2 (enExample)
KR (1) KR20140063583A (enExample)
CN (1) CN103781484A (enExample)
AU (1) AU2012283915B2 (enExample)
BR (1) BR112014001335A2 (enExample)
CA (1) CA2841964A1 (enExample)
DK (1) DK2734212T3 (enExample)
ES (1) ES2646226T3 (enExample)
IL (1) IL230433A0 (enExample)
IN (1) IN2014CN00315A (enExample)
MX (1) MX350463B (enExample)
MY (1) MY166036A (enExample)
NO (1) NO2854815T3 (enExample)
WO (1) WO2013013076A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522343A1 (en) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス, インコーポレイテッド 遺伝子発現と疼痛
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2017151644A1 (en) * 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20180025116A1 (en) * 2016-07-22 2018-01-25 Arizona Board Of Regents On Behalf Of University Of Arizona Clinical Event Management and Communication System
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN111494446B (zh) * 2020-05-18 2021-08-17 深圳市宝安中医院(集团) 治疗胆绞痛的中药组合物及其应用
WO2023034293A1 (en) * 2021-08-31 2023-03-09 Ethismos Research, Inc. Methods of preventing and treating pain and associated symptoms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA949182B (en) 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
EP1467770A1 (en) 2002-01-15 2004-10-20 ALTANA Pharma AG Pantoprazole cyclodextrin inclusion complexes
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7387194B2 (en) * 2003-11-04 2008-06-17 Otis Elevator Company Automatic passenger conveyor slow speed operation
DE602004025151D1 (de) 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
EP2522343A1 (en) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
MX2008012496A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina.
CN101264086A (zh) 2007-03-14 2008-09-17 南京师范大学 含有头孢克肟环糊精包合物的药物组合物及其制备方法
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US7662858B2 (en) * 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain

Also Published As

Publication number Publication date
EP2734212A4 (en) 2014-12-24
JP6320917B2 (ja) 2018-05-09
AU2012283915A1 (en) 2014-02-06
US20140221490A1 (en) 2014-08-07
MX350463B (es) 2017-09-06
JP2014520893A (ja) 2014-08-25
DK2734212T3 (da) 2017-11-06
WO2013013076A1 (en) 2013-01-24
NO2854815T3 (enExample) 2018-04-21
CA2841964A1 (en) 2013-01-24
JP2017110022A (ja) 2017-06-22
MY166036A (en) 2018-05-21
BR112014001335A2 (pt) 2017-02-21
KR20140063583A (ko) 2014-05-27
EP2734212A1 (en) 2014-05-28
MX2014000744A (es) 2014-05-14
CN103781484A (zh) 2014-05-07
EP3257505A1 (en) 2017-12-20
ES2646226T3 (es) 2017-12-12
AU2012283915B2 (en) 2016-11-24
EP2734212B1 (en) 2017-09-06
IL230433A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
MX2014000744A (es) Métodos de tratamiento del dolor.
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
MX377157B (es) Preparación para usarse en el tratamiento de un cáncer positivo de gd2.
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
NZ628433A (en) Chitosan-derived compositions
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX364643B (es) USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
RU2011143250A (ru) Способ анестезии при хирургическом лечении косоглазия у детей
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
MY169877A (en) Treatment of malphigia coccigera on liver cirrhosis
MX2013006633A (es) Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes.